NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News

$3.06

+0.03 (+0.99%)

(As of 09/29/2023 ET)

Compare

Today's Range: $3.05
▼
$3.19
50-Day Range: $2.16
▼
$3.48
52-Week Range: $1.77
▼
$4.05

Volume: 1,663 shs
Average Volume: 6,677 shs
Market Capitalization: $78.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

Anebulo Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 118.2% Upside
$6.67 Price Target
Short Interest: Healthy
0.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

601st out of 970 stocks

Pharmaceutical Preparations Industry

286th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
Anebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.67, Anebulo Pharmaceuticals has a forecasted upside of 118.2% from its current price of $3.06.
Amount of Analyst Coverage
Anebulo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.48% of the float of Anebulo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Anebulo Pharmaceuticals has recently increased by 1,444.44%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Anebulo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Anebulo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANEB.

3.0

News and Social Media Coverage

News Sentiment
Anebulo Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for ANEB on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Anebulo Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.70% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.44% of the stock of Anebulo Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Anebulo Pharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anebulo Pharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anebulo Pharmaceuticals has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Price History

30 days | 90 days | 365 days | Advanced Chart

ANEB Stock News Headlines

September 28, 2023 | americanbankingnews.com

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) to Post Q3 2024 Earnings of ($0.11) Per Share, HC Wainwright Forecasts

September 26, 2023 | americanbankingnews.com

Anebulo Pharmaceuticals (NASDAQ:ANEB) Receives Buy Rating from HC Wainwright

September 30, 2023 | Weiss Ratings (Ad)

Overlooked AI Stock Gets Urgent "Buy"

We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.

September 25, 2023 | msn.com

HC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy Recommendation

September 25, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)

September 23, 2023 | nasdaq.com

Maxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy Recommendation

September 23, 2023 | americanbankingnews.com

Anebulo Pharmaceuticals (NASDAQ:ANEB) Coverage Initiated by Analysts at Maxim Group

September 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)

September 30, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 21, 2023 | americanbankingnews.com

Brokers Set Expectations for Anebulo Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ANEB)

September 20, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

September 18, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy Recommendation

September 18, 2023 | markets.businessinsider.com

Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says

September 18, 2023 | markets.businessinsider.com

Anebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. Wainwright

August 30, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

August 22, 2023 | finance.yahoo.com

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001

August 21, 2023 | markets.businessinsider.com

Anebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 Approval

August 21, 2023 | finance.yahoo.com

Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

May 30, 2023 | finance.yahoo.com

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully

May 19, 2023 | finance.yahoo.com

Down -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)

May 18, 2023 | msn.com

Benchmark Reiterates Anebulo Pharmaceuticals (ANEB) Speculative Buy Recommendation

May 11, 2023 | finanznachrichten.de

Anebulo Pharmaceuticals, Inc.: Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023 | msn.com

Anebulo Pharmaceuticals: Q3 Earnings Insights

May 11, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

March 29, 2023 | msn.com

Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication

March 28, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

March 8, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

See More Headlines

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Company Calendar

Last Earnings: 11/12/2021
Today: 9/30/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANEB
CUSIP: N/A
CIK: 1815974
Web: www.anebulo.com
Phone: 512-598-0931
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.67
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +118.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.67%
Return on Assets: -74.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.92
Quick Ratio: 9.68

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.65 per share
Price / Book: 4.70

Miscellaneous

Outstanding Shares: 25,630,000
Free Float: 3,666,000
Market Cap: $78.30 million
Optionable: Not Optionable
Beta: -1.39

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Joseph F. Lawler M.D. (Age 51)
Ph.D., Founder & Chairman
Comp: $11k

Mr. Simon J. Allen B.Sc. (Age 55)
M.B.A., MBA, CEO & Director
Comp: $450k

Dr. Kenneth C. Cundy Ph.D. (Age 64)
Chief Scientific Officer
Comp: $345.53k

Ms. Sandra A. Gardiner (Age 57)
Acting Chief Financial Officer

Mr. Scott L. Anderson
Head of Investor Relations & Public Affairs

Key Competitors

View All Competitors

ANEB Stock - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings or view top-rated stocks.
What is Anebulo Pharmaceuticals' stock price forecast for 2023?: 3 Wall Street research analysts have issued twelve-month price targets for Anebulo Pharmaceuticals' stock. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price.
View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts.
How have ANEB shares performed in 2023?: Anebulo Pharmaceuticals' stock was trading at $2.4237 at the start of the year. Since then, ANEB shares have increased by 26.0% and is now trading at $3.0550.
View the best growth stocks for 2023 here.
Are investors shorting Anebulo Pharmaceuticals?: Anebulo Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 13,900 shares, an increase of 1,444.4% from the August 31st total of 900 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.5% of the company's stock are sold short.
View Anebulo Pharmaceuticals' Short Interest.
When is Anebulo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ANEB earnings forecast.
How were Anebulo Pharmaceuticals' earnings last quarter?: Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04.

When did Anebulo Pharmaceuticals IPO?: (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.
What is Anebulo Pharmaceuticals' stock symbol?: Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."
How do I buy shares of Anebulo Pharmaceuticals?: Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anebulo Pharmaceuticals' stock price today?: One share of ANEB stock can currently be purchased for approximately $3.06.
How much money does Anebulo Pharmaceuticals make?: Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $78.30 million. The company earns $-11,730,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.
How can I contact Anebulo Pharmaceuticals?: The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com.

This page (NASDAQ:ANEB) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial